Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 12/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18407974 | 1.00 | OPRM1 (0.57) | OPRM1OPRD1OPRK1SIGMAR1NOTUM | |
| SCHEMBL18407954 | 0.82 | OPRM1 (0.57) | OPRM1OPRD1OPRK1SIGMAR1NOTUM | |
| SCHEMBL1207656 | 0.82 | OPRM1 (0.57) | OPRM1OPRD1OPRK1SIGMAR1NOTUM | |
| SCHEMBL18407995 | 0.78 | OPRD1 (0.63) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL1207662 | 0.78 | OPRD1 (0.63) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL18408128 | 0.77 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL1206273 | 0.77 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL1206692 | 0.77 | OPRM1 (0.59) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL18408180 | 0.77 | OPRM1 (0.59) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL2582641 | 0.77 | OPRM1 (0.59) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220048-B1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2220048-B1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-8859580-B2 | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859580-B2 | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859580-B2 | Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2245014-B1 | UREA DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2245014-B1 | UREA DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110028445-A1 | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028445-A1 | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028445-A1 | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| WO-2009063061-A2 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028445-A1 | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | XDH, HSD11B1, HSD3B1 | OPRM1 21/4885OPRD1 29/4885OPRK1 34/4885 |
| US-20110190262-A1 | Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | HSD3B1, CYP11B1, HSD11B1 | OPRM1 129/4885OPRD1 70/4885OPRK1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.